278 related articles for article (PubMed ID: 34106303)
1. Population pharmacokinetic and exploratory exposure-response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study.
Wang B; Deng R; Hennig S; Badovinac Crnjevic T; Kaewphluk M; Kågedal M; Quartino AL; Girish S; Li C; Kirschbrown WP
Cancer Chemother Pharmacol; 2021 Sep; 88(3):499-512. PubMed ID: 34106303
[TBL] [Abstract][Full Text] [Related]
2. Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study.
Tan AR; Im SA; Mattar A; Colomer R; Stroyakovskii D; Nowecki Z; De Laurentiis M; Pierga JY; Jung KH; Schem C; Hogea A; Badovinac Crnjevic T; Heeson S; Shivhare M; Kirschbrown WP; Restuccia E; Jackisch C;
Lancet Oncol; 2021 Jan; 22(1):85-97. PubMed ID: 33357420
[TBL] [Abstract][Full Text] [Related]
3. Development of a Subcutaneous Fixed-Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose-Finding Study.
Kirschbrown WP; Wynne C; Kågedal M; Wada R; Li H; Wang B; Nijem I; Badovinac Crnjevic T; Gasser H; Heeson S; Eng-Wong J; Garg A
J Clin Pharmacol; 2019 May; 59(5):702-716. PubMed ID: 30570763
[TBL] [Abstract][Full Text] [Related]
4. Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive breast cancer: A multidisciplinary approach.
DuMond B; Patel V; Gross A; Fung A; Weber S
J Oncol Pharm Pract; 2021 Jul; 27(5):1214-1221. PubMed ID: 33719721
[TBL] [Abstract][Full Text] [Related]
5. White Paper on the Value of Time Savings for Patients and Healthcare Providers of Breast Cancer Therapy: The Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection as an Example.
Jackisch C; Manevy F; Frank S; Roberts N; Shafrin J
Adv Ther; 2022 Feb; 39(2):833-844. PubMed ID: 34988876
[TBL] [Abstract][Full Text] [Related]
6. heredERA Breast Cancer: a phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with previously untreated HER2-positive, estrogen receptor-positive locally advanced or metastatic breast cancer.
Kuemmel S; Harper-Wynne C; Park YH; Franke F; de Laurentiis M; Schumacher-Wulf E; Eiger D; Heeson S; Cardona A; Özyilkan Ö; Morales-Vàsquez F; Metcalfe C; Hafner M; Restuccia E; O'Shaughnessy J
BMC Cancer; 2024 May; 24(1):641. PubMed ID: 38789924
[TBL] [Abstract][Full Text] [Related]
7. FDA Approval Summary: Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf Injection for Subcutaneous Use in Patients with HER2-positive Breast Cancer.
Gao JJ; Osgood CL; Gong Y; Zhang H; Bloomquist EW; Jiang X; Qiu J; Yu J; Song P; Rahman NA; Chiu HJ; Ricks TK; Rizvi F; Hou S; Wilson W; Abukhdeir AM; Seidman J; Ghosh S; Philip R; Pierce WF; Bhatnagar V; Kluetz PG; Pazdur R; Beaver JA; Amiri-Kordestani L
Clin Cancer Res; 2021 Apr; 27(8):2126-2129. PubMed ID: 33188141
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic and exploratory exposure-response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study.
Kirschbrown WP; Kågedal M; Wang B; Lindbom L; Knott A; Mack R; Monemi S; Nijem I; Girish S; Freeman C; Fumagalli D; McConnell R; Jerusalem G; Twelves C; Baselga J; von Minckwitz G; Bines J; Garg A
Cancer Chemother Pharmacol; 2019 Jun; 83(6):1147-1158. PubMed ID: 30976844
[TBL] [Abstract][Full Text] [Related]
9. Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study.
O'Shaughnessy J; Sousa S; Cruz J; Fallowfield L; Auvinen P; Pulido C; Cvetanovic A; Wilks S; Ribeiro L; Burotto M; Klingbiel D; Messeri D; Alexandrou A; Trask P; Fredriksson J; Machackova Z; Stamatovic L;
Eur J Cancer; 2021 Jul; 152():223-232. PubMed ID: 34147014
[TBL] [Abstract][Full Text] [Related]
10. Incidence and severity of anaphylaxis and hypersensitivity in trials of intravenous pertuzumab plus trastuzumab or the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection for HER2-positive breast cancer.
Swain SM; Tan AR; Gianni L; Kuemmel S; Dang CT; Schneeweiss A; O'Shaughnessy J; Liu H; Aguila C; Heeson S; Macharia H; Yang K; Restuccia E; Loibl S
Eur J Cancer; 2023 Jan; 178():70-81. PubMed ID: 36410207
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic and exposure-response analyses of pertuzumab in combination with trastuzumab and docetaxel during neoadjuvant treatment of HER2+ early breast cancer.
Quartino AL; Li H; Jin JY; Wada DR; Benyunes MC; McNally V; Viganò L; Nijem I; Lum BL; Garg A
Cancer Chemother Pharmacol; 2017 Feb; 79(2):353-361. PubMed ID: 28074265
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
[TBL] [Abstract][Full Text] [Related]
13. Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study.
Kuemmel S; Tondini CA; Abraham J; Nowecki Z; Itrych B; Hitre E; Karaszewska B; Juárez-Ramiro A; Morales-Vásquez F; Pérez-García JM; Cardona-Huerta S; Monturus E; Sequi M; Restuccia E; Benyunes M; Martín M
Breast Cancer Res Treat; 2021 Jun; 187(2):467-476. PubMed ID: 33748921
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetic and exposure-response analysis for trastuzumab administered using a subcutaneous "manual syringe" injection or intravenously in women with HER2-positive early breast cancer.
Quartino AL; Hillenbach C; Li J; Li H; Wada RD; Visich J; Li C; Heinzmann D; Jin JY; Lum BL
Cancer Chemother Pharmacol; 2016 Jan; 77(1):77-88. PubMed ID: 26645407
[TBL] [Abstract][Full Text] [Related]
15. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.
Wildiers H; Tryfonidis K; Dal Lago L; Vuylsteke P; Curigliano G; Waters S; Brouwers B; Altintas S; Touati N; Cardoso F; Brain E
Lancet Oncol; 2018 Mar; 19(3):323-336. PubMed ID: 29433963
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic and exposure-response analysis of pertuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer.
Kirschbrown WP; Wang B; Nijem I; Ohtsu A; Hoff PM; Shah MA; Shen L; Kang YK; Alsina M; Girish S; Garg A
Cancer Chemother Pharmacol; 2019 Sep; 84(3):539-550. PubMed ID: 31183514
[TBL] [Abstract][Full Text] [Related]
17. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.
Swain SM; Miles D; Kim SB; Im YH; Im SA; Semiglazov V; Ciruelos E; Schneeweiss A; Loi S; Monturus E; Clark E; Knott A; Restuccia E; Benyunes MC; Cortés J;
Lancet Oncol; 2020 Apr; 21(4):519-530. PubMed ID: 32171426
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of pertuzumab administered concurrently with trastuzumab in Chinese patients with HER2-positive early breast cancer.
Luo Y; Li W; Jiang Z; Zhang Q; Wang L; Mao Y; Tjan-Heijnen VCG; Im SA; McConnell R; Bejarano S; Fumagalli D; Bines J; Wang B; Garg A; Kirschbrown WP; Xu B
Anticancer Drugs; 2019 Sep; 30(8):866-872. PubMed ID: 31305270
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study.
Gianni L; Bisagni G; Colleoni M; Del Mastro L; Zamagni C; Mansutti M; Zambetti M; Frassoldati A; De Fato R; Valagussa P; Viale G
Lancet Oncol; 2018 Feb; 19(2):249-256. PubMed ID: 29326029
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
Gianni L; Pienkowski T; Im YH; Roman L; Tseng LM; Liu MC; Lluch A; Staroslawska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi G; Szado T; Ratnayake J; Ross G; Valagussa P
Lancet Oncol; 2012 Jan; 13(1):25-32. PubMed ID: 22153890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
